Search results for "Cardiovascular medicine"

showing 10 items of 4222 documents

Cardiovascular system in the sars-CoV-2: impact of therapies.

2021

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Physiologybusiness.industrySARS-CoV-2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)COVID-19VirologyCardiovascular SystemCardiovascular DiseasesInternal MedicineMedicineHumansCardiology and Cardiovascular MedicinebusinessJournal of hypertension
researchProduct

Plasma Antithrombin Values Are Significantly Decreased in Coronavirus Disease 2019 (COVID-19) Patients with Severe Illness

2020

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Plasma AntithrombinSeverity of Illness IndexAntithrombinsCoronavirus Disease 2019medicineHumansThrombophiliaProspective StudiesPlasma Antithrombin Coronavirus Disease 2019 COVID-19business.industryHeparinSARS-CoV-2AntithrombinAnticoagulantsCOVID-19ThrombosisHematologyDisseminated Intravascular CoagulationVirologyCross-Sectional StudiesbusinessCardiology and Cardiovascular Medicinemedicine.drug
researchProduct

Coronavirus disease 2019 infection and the cardiovascular system

2020

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralAntiviral AgentsCardiovascular SystemSettore MED/11Renin-Angiotensin SystemBetacoronavirusPandemicHumansMedicinePandemicsHost Microbial InteractionsbiologySARS-CoV-2business.industryCOVID-19General Medicinebiology.organism_classificationmedicine.diseaseVirologyCOVID-19 Drug TreatmentPneumoniaCardiovascular DiseasesCoronavirus InfectionsCardiology and Cardiovascular MedicinebusinessBetacoronavirusJournal of Cardiovascular Medicine
researchProduct

Lower ST-elevation myocardial infarction incidence during COVID-19 epidemic in Northern Europe

2020

We compared the ST elevation myocardial infarction (STEMI) incidence during COVID-19 pandemic (March 2020) to January-February 2020 and to same time period in earlier years 2017-2019 in five Nordic-Baltic tertiary centers. During 2017-2019, there were no marked differences in STEMI incidence between January, February and March. During 2020, there was an average drop of 32% in STEMI incidence in March. The isolation measures may decrease the risk for respiratory virus infection and contribute to the lower STEMI incidence and that we might benefit from firmer suggestions on hand hygiene and social distancing during flu season at least among high-risk individuals.

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)media_common.quotation_subject030204 cardiovascular system & hematologyScandinavian and Nordic CountriesTertiary Care Centers03 medical and health sciences0302 clinical medicineSt elevation myocardial infarctionHygieneRespiratory virus infectionPandemicFlu seasonMedicineHumanscardiovascular diseases030212 general & internal medicinemedia_commonRetrospective Studiesbusiness.industryIncidence (epidemiology)IncidenceCOVID-19Latvia3. Good healthsurgical procedures operativeST-elevation myocardial infarctionincidenceST Elevation Myocardial InfarctionbusinessCardiology and Cardiovascular MedicineDemography
researchProduct

Reperfusion treatment for high-risk pulmonary embolism associated with COVID-19

2020

2019-20 coronavirus outbreakbiologyCoronavirus disease 2019 (COVID-19)business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)biology.organism_classificationmedicine.diseaseVirologyPulmonary embolismPandemicmedicineCardiology and Cardiovascular MedicinebusinessBetacoronavirusCoronavirus InfectionsVasa
researchProduct

Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia.

2021

Bempedoic acid (BA) is a novel first-in-class oral lipid-lowering therapy. BA has been approved by the European Medicinal Agency and Food and Drug Administration and has been commercialised throughout Europe since the end of 2020 as an add-on therapy in patients at high/very-high cardiovascular risk that are not at LDL-C goals with current lipid-lowering treatments. Recently, Italian lipid management experts gathered to discuss several open questions on BA characteristics and BArelated practical clinical issues. The panel permitted collection of its opinions in a ten Q&A format. Aim: The aim of this viewpoint is to discuss and answer several open questions on BA characteristics and BA-r…

ATP citrate lyaseEndocrinology Diabetes and MetabolismMedicine (miscellaneous)HyperlipidemiasPharmacologyLipid-lowering therapyLipid-lowering treatmentMedicineLDL-cholesterolHumansDicarboxylic AcidsHypolipidemic AgentsLdl cholesterolNutrition and DieteticsLipid managementbusiness.industryNovel LDL-C treatment.Fatty AcidsCholesterol LDLBempedoic acidNovel LDL-C treatmentATP citrate lyaseATP citrate lyase; bempedoic acid; LDL-cholesterol; lipid-lowering treatment; novel LDL-C treatmentLipid loweringCardiology and Cardiovascular MedicinebusinessClinical evaluationBempedoic acidNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome

2020

Background: Familial chylomicronemia syndrome (FCS) is characterized by severe fasting hypertriglyceridemia, abdominal pain, and recurrent acute pancreatitis. Available triglyceride-lowering drugs are insufficient to avoid pancreatitis. Therefore, there is a significant unmet medical need for effective triglyceride-lowering drugs for patients with FCS. Case report: We report the second case of a patient with FCS and recurrent pancreatitis treated with lomitapide. Lomitapide treatment resulted in a reduction of fasting TG levels from 2897 mg/dL (32.71 mmol/L) to an average of 954 mg/dL (10.77 mmol/L) on the 30 mg lomitapide equating to a 67% reduction from baseline. After 26 months of lomita…

Abdominal painPediatricsmedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyRecurrent pancreatitisInternal medicineFatty liverHumansMedicineProspective Studiesmedicine.diagnostic_testbusiness.industryFatty liverHypertriglyceridemiaFCSFamilial Chylomicronemiamedicine.diseaseLomitapideLomitapideAcute pancreatitisPancreatitischemistry030220 oncology & carcinogenesisLiver biopsyAcute DiseaseAcute pancreatitisPancreatitisBenzimidazolesHyperlipoproteinemia Type Ilipids (amino acids peptides and proteins)medicine.symptomCardiology and Cardiovascular MedicinebusinessFamilial chylomicronaemia syndromeAtherosclerosis
researchProduct

Release kinetics of early ischaemic biomarkers in a clinical model of acute myocardial infarction

2014

ObjectiveTo determine the release kinetics of different biomarkers with potential as novel early ischaemic biomarkers in patients with acute coronary syndrome (ACS); it is difficult to establish the detailed release kinetics in patients with acute myocardial infarction (AMI).MethodsWe analysed the release kinetics of soluble fms-like tyrosine kinase (sFlt-1), ischaemia modified albumin (IMA), and heart-type fatty acid binding protein (hFABP) in patients with hypertrophic obstructive cardiomyopathy who were undergoing transcoronary ablation of septal hypertrophy (TASH), a procedure mimicking AMI. Consecutive patients (n=21) undergoing TASH were included. Blood samples were collected before T…

Ablation TechniquesMalemedicine.medical_specialtyAcute coronary syndromeMyocardial InfarctionCardiomyopathySerum albuminSerum Albumin HumanFatty Acid-Binding ProteinsFatty acid-binding proteinPredictive Value of TestsInternal medicineHumansMedicineMyocardial infarctionSerum AlbuminAgedImmunoassayVascular Endothelial Growth Factor Receptor-1biologybusiness.industryCardiomyopathy HypertrophicMiddle Agedmedicine.diseaseUp-RegulationKineticsEarly DiagnosisPredictive value of testsbiology.proteinCardiologyFemaleFatty Acid Binding Protein 3Myocardial infarction diagnosisCardiology and Cardiovascular MedicinebusinessFatty Acid Binding Protein 3BiomarkersHeart
researchProduct

Endovenous ablation of refluxing saphenous and perforating veins.

2017

Abstract. Since the end of the nineties endovenous thermal ablation and more recently non-thermal, non-tumescent techniques have been developed and improved. Until now, because of their favourable side effect profile in conjunction to sustained efficacy, in many countries they already replaced high ligation and stripping in the treatment of refluxing saphenous veins as well as for treatment of perforators and selected tributaries. Now, studies and comparative trials are available with long-term follow-ups for most of the techniques, providing valid data on occlusion and reflux rates, side effect profiles, and health related quality of life.

Ablation Techniquesmedicine.medical_specialtyTime FactorsSide effectRadiofrequency ablationThermal ablation030204 cardiovascular system & hematologylaw.invention030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinePostoperative ComplicationslawRisk FactorsOcclusionMedicineHumansSaphenous VeinHealth related quality of lifebusiness.industryEndovenous ablationComparative trialSurgerySteamTreatment OutcomeVenous InsufficiencyCatheter AblationLaser TherapyPerforating veinsCardiology and Cardiovascular MedicinebusinessVASA. Zeitschrift fur Gefasskrankheiten
researchProduct

Impact of monitoring on detection of arrhythmia recurrences in the ESC-EHRA EORP atrial fibrillation ablation long-term registry

2019

Abstract Aims Monitoring of patients after ablation had wide variations in the ESC-EHRA atrial fibrillation ablation long-term (AFA-LT) registry. We aimed to compare four different monitoring strategies after catheter AF ablation. Methods and results The ESC-EHRA AFA-LT registry included 3593 patients who underwent ablation. Arrhythmia monitoring during follow-up was performed by 12-lead electrocardiogram (ECG), Holter ECG, trans-telephonic ECG monitoring (TTMON), or an implanted cardiac monitoring (ICM) system. Patients were selected to a given monitoring group according to the most extensive ECG tool used in each of them. Comparison of the probability of freedom from recurrences was perfo…

Ablation Techniquesmedicine.medical_specialtymedicine.medical_treatmentAftercareKaplan-Meier EstimateElectrocardiographyRecurrencePhysiology (medical)Internal medicineAtrial FibrillationmedicineHumansTelemetryRegistriescardiovascular diseasesMonitoring methodsbusiness.industryCardiac arrhythmiaAtrial fibrillationmedicine.diseaseAblationTelephoneEcg monitoringCatheterElectrocardiography AmbulatoryCardiologyCardiac monitoringCardiology and Cardiovascular MedicinebusinessHolter ecgEP Europace
researchProduct